Drugs / SKB518
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06428331 | Jul 2024 → Jun 2026 overdue | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07448922 | Apr 2026 → Dec 2027 expected | female reproductive organ cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07019675 | Aug 2025 → Feb 2027 expected | lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-21 | Klus Pharma Inc. | Regulatory Kelun-Biotech’s novel ADC drug SKB518 receives IND clearance from U.S. Food and Drug Administration (FDA) kluspharma.com ↗
Kelun-Biotech’s novel ADC drug SKB518 has just recently been granted IND clearance from the United States Food and Drug Administration (FDA). |
| 2024-06-18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech ADC Innovator SKB518 for Advanced Solid Tumors Receives CDE Clinical Trial Approval Notification kelun-biotech.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-21 | Klus Pharma Inc. | Kelun-Biotech’s novel ADC drug SKB518 receives IND clearance from U.S. Food and Drug Administration (FDA) kluspharma.com ↗ |
| 2024-06-18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech ADC Innovator SKB518 for Advanced Solid Tumors Receives CDE Clinical Trial Approval Notification kelun-biotech.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB518 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06428331 ↗ |